|Mr. Lewis G. Gradon||MD, CEO & Exec. Director||2.32M||N/A||1961|
|Ms. Lyndal York||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Andrew Somervell||VP of Products & Technology||N/A||N/A||N/A|
|Hayden Brown||Investor Relations Mang.||N/A||N/A||N/A|
|Karen Knott||Sr. Communications Mang.||N/A||N/A||N/A|
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It provides its products for use in respiratory care, acute care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers myAIRVO 2, a humidifier with integrated flow source; Optiflow, a nasal high flow therapy; and noninvasive and invasive ventilation systems. It also provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. In addition, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Fisher & Paykel Healthcare Corporation Limited’s ISS governance QualityScore as of 9 December 2019 is 6. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 4; Compensation: 9.